Successful Introduction of Lorlatinib After Drug Eruption With Alectinib in ALK ‐Positive Lung Adenocarcinoma: A Case Report
Respirology Case Reports · 2026-07 · 14 (7)
DOI: 10.1002/rcr2.70671 ↗Kurz gefasst
Fallbericht in der Zeitschrift Respirology Case Reports, online erschienen am 15.07.2026. Verfasst von Shunsuke Omura und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary Medicine Tokyo Saiseikai Central Hospital Tokyo Japan. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Anaplastic lymphoma kinase (ALK) fusion genes are detected in approximately 3%–5% of non‐small cell lung cancers (NSCLC). Alectinib and lorlatinib are ALK tyrosine kinase inhibitors with established efficacy; however, their adverse event profiles differ. We report a 61‐year‐old man with recurrent ALK‐positive lung adenocarcinoma who developed a grade 2 drug eruption consistent with fixed drug eruption during alectinib therapy. The rash resolved following drug discontinuation and corticosteroid treatment. Lorlatinib was subsequently initiated without recurrence of cutaneous toxicity. Apart from Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 dyslipidemia, no significant adverse events occurred, and partial response has been maintained for over 1 year. This case suggests that lorlatinib may be a feasible alternative in patients who develop cutaneous adverse reactions to alectinib, enabling continuation of targeted therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Pulmonary Medicine Tokyo Saiseikai Central Hospital Tokyo Japan.
- Division of Pulmonary Medicine, Department of Medicine Keio University School of Medicine Tokyo Japan.
ORCID-Profile: Tetsuo Tani, Saeko Takahashi
Zitieren
APA
Omura, S., Sunata, K., Tani, T., Uchibori, K., Shinomiya, S., & Takahashi, S. (2026). Successful Introduction of Lorlatinib After Drug Eruption With Alectinib in ALK ‐Positive Lung Adenocarcinoma: A Case Report. Respirology Case Reports, 14(7). https://doi.org/10.1002/rcr2.70671
Vancouver
Omura S, Sunata K, Tani T, Uchibori K, Shinomiya S, Takahashi S. Successful Introduction of Lorlatinib After Drug Eruption With Alectinib in ALK ‐Positive Lung Adenocarcinoma: A Case Report. Respirology Case Reports. 2026;14(7). doi:10.1002/rcr2.70671
BibTeX
@article{Omura2026,
author = {Omura, Shunsuke and Sunata, Keeya and Tani, Tetsuo and Uchibori, Koyuru and Shinomiya, Shun and Takahashi, Saeko},
title = {Successful Introduction of Lorlatinib After Drug Eruption With Alectinib in ALK ‐Positive Lung Adenocarcinoma: A Case Report},
journal = {Respirology Case Reports},
year = {2026},
volume = {14},
number = {7},
doi = {10.1002/rcr2.70671}
}
EUVIMED